Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its multiple myeloma treatment. Waltham, Mass.-based Oncopeptides' Port study is an open-label, randomized, crossover study comparing the safety, … [Read More...] about Oncopeptides completes enrollment in Phase 2 multiple myeloma study
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Insulet shares down after Q1 miss
Insulet (NSDQ:PODD) stock is down today — a day after the wearable insulin delivery system developer posted break-even Q1 results that were lower than analysts’ expectations. The company, however, yesterday evening raised the low end of its … [Read More...] about Insulet shares down after Q1 miss
Ocular Therapeutix misses The Street on bottom-line leap
Ocular Therapeutix (NSDQ:OCUL) reported first-quarter results that missed the consensus forecast on Wall Street. The Bedford, Mass.–based eye disease therapeutic developer yesterday posted profits of $3.12 million, or $0.04 per share, on sales of … [Read More...] about Ocular Therapeutix misses The Street on bottom-line leap
Tandem Diabetes Care beats The Street in Q1, raises guidance
Tandem Diabetes Care (NSDQ:TNDM) narrowed its losses year-over-year in Q1, with results beating the consensus forecast on Wall Street. The San Diego-based company yesterday evening posted losses of –$5 million, or –8¢ per share, on sales of $141 … [Read More...] about Tandem Diabetes Care beats The Street in Q1, raises guidance
BD to spin off its diabetes business, Q2 earnings beat The Street
BD (NYSE: BDX) announced today that it will spin off its Diabetes Care business as an independent, publicly traded company during the first half of 2022. The Diabetes Care business saw $1.1 billion in sales during BD's fiscal year ended Sept. 30, … [Read More...] about BD to spin off its diabetes business, Q2 earnings beat The Street
Lilly partners with four companies on insulin pen tech
Eli Lilly (NYSE:LLY) today announced deals with four companies whose diabetes management tech will work with Lilly's latest insulin pen. The Tempo Pen is a modified version of Lilly's existing prefilled, disposable insulin pen to which the Tempo … [Read More...] about Lilly partners with four companies on insulin pen tech
Oncopeptides completes enrollment in Phase 2 multiple myeloma study
Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its multiple myeloma treatment. Waltham, Mass.-based Oncopeptides' Port study is an open-label, randomized, crossover study comparing the safety, … [Read More...] about Oncopeptides completes enrollment in Phase 2 multiple myeloma study
United Therapeutics posts Street-beating Q1
United Therapeutics (NSDQ:UTHR) today announced first-quarter results that came in well ahead of the consensus forecast. The Research Triangle Park, N.C.-based company posted profits of $28.3 million, or 61¢ per share, on sales of $379.1 million … [Read More...] about United Therapeutics posts Street-beating Q1
Kala Pharmaceuticals rises before hours on mixed bag Q1
Kala Pharmaceuticals (NSDQ:KALA) announced shares ticked up before hours today on first-quarter results that were mixed compared to the consensus forecast. The Watertown, Mass.-based company posted losses of -$30.4 million, or -49¢ per share, on … [Read More...] about Kala Pharmaceuticals rises before hours on mixed bag Q1
Teva Pharmaceuticals launches generic Erythromycin tablets in U.S.
Teva Pharmaceuticals (NYSE:TEVA) announced today that it launched generic Erythromycin oral tablets in the U.S. Parsippany, N.J.-based Teva — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries — launched the 250 mg- and 500 … [Read More...] about Teva Pharmaceuticals launches generic Erythromycin tablets in U.S.
Most pharma executives see digital drug delivery as important, Molex says
A survey conducted by Molex and its Phillips-Medisize medical device delivery division highlights the importance of digitized drug delivery. Lisle, Ill.-based Molex and Phillips-Medisize commissioned Dimensional Research to poll 215 pharmaceutical … [Read More...] about Most pharma executives see digital drug delivery as important, Molex says
In case you missed it
- Smiths Medical partners with Ivenix on infusion management suite
- Gyroscope Therapeutics launches IPO roadshow
- BD’s Alaris pump hit with another serious recall
- FDA approves higher dosage of naloxone nasal spray
- Bexson Biomedical wins U.S. patent for ketamine formulation
- Dexcom dips after hours despite Street-beating Q1, raised guidance
- Vascular Therapies touts surgical stenosis treatment trial despite missed primary endpoint
- West Pharmaceutical Services beats Street in Q1, raises guidance
- Merck comes up short on Q1 forecast
- Teva Pharmaceuticals unchanged before hours on Q1 earnings beat
- Canada approves J&J Vision’s drug-eluting contact lens
- Valeo Pharma closes upsized $6.6M private placement
- Timberlake appointed as Berkshire Biomedical CEO
- FDA grants breakthrough nod for Fractyl’s type 2 diabetes treatment
- BD applies to start shipping Alaris pumps again
Clinical Trials
Oncopeptides completes enrollment in Phase 2 multiple myeloma study
Oncopeptides announced today that it completed patient enrollment for its Phase 2 Port study of its multiple myeloma treatment. Waltham, Mass.-based Oncopeptides’ Port study is an open-label, randomized, crossover study comparing the safety, tolerability and efficacy of peripheral or central intravenous administration of Pepaxto (melphalan flufenamide) in combination with dexamethasone to treat relapsed refractory multiple […]
Vascular Therapies touts surgical stenosis treatment trial despite missed primary endpoint
Vascular Therapies announced today that a Phase 3 clinical trial of its Sirogen sirolimus formulation showed encouraging outcomes. Cresskill, N.J.-based Vascular Therapies designed its Sirogen proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. The Phase 3 clinical trial evaluated Sirogen in elderly end-stage renal disease patients, according to […]
FDA grants breakthrough nod for Fractyl’s type 2 diabetes treatment
Fractyl Laboratories announced today that it received FDA breakthrough device designation for its Revita DMR type 2 diabetes treatment. Lexington, Mass.-based Fractyl’s Revita DMR treatment is an outpatient endoscopic procedure designed to resurface the upper intestine lining (duodenal mucosa) in metabolic disease for patients with insulin-treated type 2 diabetes. Preliminary clinical findings suggest that the […]
Delpor doses first patient in once-yearly risperidone implant trial
Delpor announced today that it dosed the first patient in a Phase 1b/2a clinical trial for its DLP-114 risperidone implant. DLP-114 is a long-acting formulation of the antipsychotic risperidone for schizophrenia maintenance therapy. The open-label study is to evaluate the safety, tolerability and pharmacokinetics of switching from oral risperidone to the once- or twice-yearly DLP-114 […]
Cure Pharmaceutical touts data from Curefilm Blue trial for erectile dysfunction
Cure Pharmaceutical announced today that it observed positive results from a trial for its Curefilm Blue platform. Oxnard, Calif.-based Cure touted the results of its initial pharmacokinetics (PK)/bioequivalence studies ahead of the advancement of its clinical program in pursuit of FDA approval, according to a news release. The company did not reveal the specific data, […]
